An Environmental Scan and Evaluation of Quality Indicators Across Canadian Kidney Transplant Centers

Tamara Glavinovic1, Amanda J. Vinson2, Samuel A. Silver3, and Seychelle Yohanna4

Abstract

Background: Kidney transplantation is the optimal treatment for an individual requiring kidney replacement therapy, resulting in improved survival and quality of life while costing the health care system less than maintenance dialysis. Achieving and maintaining a kidney transplant requires extensive coordination of several different health care services. To improve the quality of kidney transplant care, quality metrics or indicators that encompass all aspects of the individual’s journey to transplant should be measured in a standardized fashion.

Objective: To identify, categorize, and evaluate strengths and weaknesses of kidney transplant quality indicators currently being used across Canada.

Design: An environmental scan of quality indicators being used by kidney organizations and programs.

Setting: A 16-member volunteer pan-Canadian panel with expertise in nephrology, transplant, and quality improvement.

Sample: Transplant programs, as well as provincial transplant and kidney agencies across Canada.

Methods: Indicators were first categorized based on the period of transplant care and then using the Institute of Medicine and Donabedian frameworks. A 4-member subcommittee rated each indicator using a modified version of the Delphi consensus technique based on the American College of Physician/Agency for Healthcare Research and Quality criteria. Consensus ratings were subsequently shared with the entire 16-member panel for additional comments.

Results: We identified 46 measures related to transplant care across 7 Canadian provinces (9 referral and evaluation, 9 waitlist activity and outcomes, 6 hospitalization for transplant surgery, 12 posttransplant care, 6 organ utilization, 4 living donor). We rated 24 indicators (52%) as necessary to distinguish high-quality from low-quality care, most of which measured effective (n = 10) or efficient (n = 6) care. Only 7 (15%) of 46 indicators evaluated person-centered or equitable care. Fourteen common indicators were measured by 5 of 7 provinces, 10 of which were deemed “necessary,” measuring safe (n = 2), effective (n = 5), efficient (n = 2), and equitable (n = 1) care.

Limitations: The panel lacked patient and allied health representation.

Conclusions: There are a large number of kidney transplant quality indicators currently being used in Canada, some of which are common across provinces and focus primarily on measuring effective care. Person-centered and equitable care indicators were lacking, and only half of these indicators were deemed “necessary” for quality improvement. Our results should complement ongoing work to achieve national consensus on the standardization of quality indicators in kidney transplantation.

Abrégé

Contexte: La transplantation rénale constitue le traitement optimal pour une personne nécessitant une thérapie de remplacement rénal. La greffe améliore la survie et la qualité de vie du patient, tout en s’avérant moins coûteuse pour le système de santé que la dialyse d’entretien. La réussite et le maintien d’une transplantation rénale requièrent la parfaite coordination de plusieurs services de santé différents. L’amélioration des soins entourant la greffe passe donc par la mesure normalisée des indicateurs de qualité qui englobent tous les aspects du cheminement du patient vers la transplantation.

Objectifs: Identifier, classer et évaluer les forces et faiblesses des indicateurs actuellement utilisés au Canada pour mesurer la qualité des soins entourant la transplantation rénale.

Type d’étude: Analyse contextuelle des indicateurs de la qualité utilisés par les organismes et programmes de néphrologie.

Cadre: Un comité bénévole pancanadien composé de 16 personnes détenant une expertise en néphrologie, en transplantation et en amélioration de la qualité.
Échantillon: Les programmes de transplantation et les organismes provinciaux de transplantation et de néphrologie partout au Canada.

Méthodologie: Les indicateurs ont d’abord été catégorisés selon le moment des soins, puis avec les modèles de l’Institute of Medicine et de Donabedian. Un sous-comité de quatre personnes a évalué les indicateurs à l’aide d’une version modifiée de la méthode Delphi basée sur les critères de l’American College of Physicians/Agency for Healthcare Research and Quality. Les évaluations consensuelles ont ensuite été partagées avec les 16 membres du comité afin de recueillir d’autres commentaires.

Résultats: Nous avons recensé 46 mesures liées aux soins de transplantation dans sept provinces canadiennes (9 aiguillages et évaluations, 6 hospitalisations en vue d’une greffe, 12 soins post-transplantation, 6 utilisations d’organes et 4 donneurs vivants). Nous avons évalué 24 indicateurs (52 %) comme étant nécessaires pour départager les soins de haute qualité des soins de mauvaise qualité, la plupart mesurant l’efficacité (n = 10) ou l’efficience (n = 6). Seuls 7 indicateurs sur 46 (15 %) évaluaient des soins équitables ou axés sur la personne. Quatorze indicateurs communs étaient mesurés par cinq des sept provinces. Parmi eux, dix mesurant des soins sûrs (n = 2), efficaces (n = 5), équitables (n = 2) et équitables (n = 1) ont été jugés « nécessaires ».

Limites: Le comité manquait de représentation parmi les patients et les professionnels paramédicaux.

Conclusion: Un grand nombre d’indicateurs de la qualité de la transplantation rénale sont utilisés au Canada, certains sont communs à plusieurs provinces et mettent principalement l’accent sur l’efficacité des soins. Mais seulement la moitié de ceux-ci ont été jugés « nécessaires » pour améliorer la qualité. De plus, des indicateurs quant aux soins équitables et axés sur la personne manquaient. Nos résultats devraient compléter les travaux en cours visant l’obtention d’un consensus national sur la normalisation des indicateurs de qualité en transplantation rénale.

Keywords
kidney transplantation, kidney replacement therapy, transplant outcomes, quality indicators, quality improvement

What was known before
Kidney transplant is a cost-effective method of kidney replacement therapy that improves patient survival and quality of life. Caring for individuals before and after transplant requires extensive coordination of care to ensure excellent outcomes, yet it is unclear how quality of care is being measured in Canada.

What this adds
This environmental scan identified 46 kidney transplant quality indicators across Canada. Despite the large number of indicators and some provincial overlap, there were notable gaps in the measurement of person-centered and equitable care. This work both provides a resource of existing quality indicators in kidney transplant and informs future efforts that aim to standardize the measurement of quality in kidney transplant care.

Introduction
Kidney transplantation is the optimal treatment for individuals requiring kidney replacement therapy (KRT) as it results in improved survival, enhanced quality of life, and reduced health care costs compared with maintenance dialysis.1-4 For an individual with kidney failure, achieving and maintaining a kidney transplant long-term require extensive oversight, expertise, and coordination of health care services across various health care sectors (eg, hospital transplant programs, organ procurement organizations, chronic kidney disease programs, primary care). Many challenges to providing high-quality kidney transplant care exist, including lack of access demonstrated by variability in referral and transplant rates across programs, prolonged recipient and donor evaluation wait times, and stagnant living donor numbers.5-8 To understand whether transplant programs are providing high-quality care and to facilitate improvement activities, a comprehensive view of the individual’s journey

1Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada
2Department of Medicine, Division of Nephrology, Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada
3Department of Medicine, Division of Nephrology, Kingston Health Sciences Centre, Queen’s University, Kingston, ON, Canada
4Department of Medicine, Division of Nephrology, St. Joseph’s Healthcare Hamilton, McMaster University, Hamilton, ON, Canada

*Both authors contributed equal supervision to this work.

Corresponding Author:
Tamara Glavinovic, Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto, 1929 Bayview Ave., Rm 378, Toronto, ON M4G 3E8, Canada.
Email: tamara.glavinovic@mail.mcgill.ca
to transplant and beyond must be translated into measurable quality-of-care metrics (or quality indicators). However, few examples of how to measure the quality of kidney transplant care exist in Canada.9,10

Quality indicators are quantitative or qualitative measures that can be described with different frameworks. The Institute of Medicine (IOM) domains determine whether the care provided is safe (free from harm), effective (evidence-based), efficient (limits waste), timely (available when needed), person-centered (focused on the individual), and equitable (equally available).11 Quality indicators can also be categorized into 3 aspects of quality described in the Donabedian framework: structure measures (the setting in which kidney transplantation occurs, for example, the presence of a multidisciplinary team), process measures (the steps to deliver care, for example, the proportion of recipients on pneumocystis jiroveci [PJP] prophylaxis), and outcome measures (how that care will impact the individual, for example, graft survival).12 Not only can quality indicators determine whether predefined benchmarks are met (ie, quality assurance), but they can also be used by frontline health care providers for microsystem quality improvement (ie, small-scale projects that test iterative changes aiming to improve local performance).13

In Canada, transplant programs are somewhat siloed, and little is known about the provincial scope and overlap of existing quality indicators and the different domains of health care quality currently being measured in kidney transplantation. The objective of this study was to identify and describe the characteristics of kidney transplant quality indicators currently being used in Canada, as well as to highlight their strengths and weaknesses based on the American College of Physicians/Agency for Healthcare Research Quality performance measure review criteria,14 We anticipate this work will provide a pan-Canadian resource of existing quality indicators and complement future studies that aim to standardize the use and operationalize definitions for quality indicators used in kidney transplant care.

Methods

Environmental Scan of Quality Indicators

We collected kidney transplant quality indicators currently in use by provincial agencies and transplant programs within Canada between February 2019 and December 2020. We also asked programs to provide examples of any ongoing or past quality improvement initiatives related to transplant care. We contacted leadership from provincial agencies, nephrology division directors, transplant program administrative directors, and transplant nephrologists across Canada. We stopped the environmental scan once we received multiple responses from the majority of provinces and received no further feedback from other provinces.

We combined quality indicators into a single measure where similarities existed (eg, the proportion of individuals treated with maintenance dialysis referred for transplant was combined with the proportion of individuals treated with maintenance dialysis referred for transplant stratified by type of dialysis modality). Next, we organized each indicator into categories of transplant care (eg, referral and evaluation, waitlist activity and outcomes, hospitalization for transplant surgery, posttransplant care, organ utilization, living donor). We then classified indicators using the IOM (safe, effective, efficient, timely, person-centered, equitable) and Donabedian (structure, process, outcome) frameworks of health care quality. We also included balancing measures to evaluate any unintended negative effects that occur with provision of care (ie, infectious complications of immunosuppression).15

Indicator Evaluation

We rated the identified indicators using a modified version of the American College of Physicians/Agency for Healthcare Research and Quality performance measure review criteria, which included the following dimensions (Supplemental Table 1):13,16,17

- Importance: The metric will lead to a measurable and meaningful improvement, or there is a clear performance gap.
- Evidence base: The metric is based on high-quality and high-quantity evidence.
- Measure specifications: The metric can be clearly defined (ie, numerator and denominator) and reliably captured.
- Feasibility and applicability: The metric is under the influence of health care providers and/or the health care system, with data collection and improvement activities both feasible and acceptable.

We rated each of these dimensions on a 9-point scale, where 1-3 indicated “does not meet criteria,” 4-6 “meets some criteria,” and 7-9 “meets criteria.” Based on these ratings, each indicator then received a final global rating based on its overall ability to distinguish good quality from poor quality.16 For the global rating, we considered quality indicators as “necessary” if the median rating was 7, 8, or 9 and there was no disagreement by any member. We considered indicators as “unnecessary” if the median rating was 1, 2, or 3 and there was no disagreement by any member. We considered all other indicators as “supplemental.”

Overview of the Modified Delphi Process

We used a modified Delphi approach to evaluate the strengths and weaknesses of different transplant indicators. This process has been described previously to help classify quality indicators.15,18-24 The Delphi panel consisted of a 16-member volunteer national nephrology quality indicator committee with representatives from 7 of 10 provinces. The majority of members possessed advanced training or expertise in quality
improvement. From this committee, a 4-person kidney transplant subcommittee was formed.

The quality indicators from the environmental scan were made available to the kidney transplant subcommittee. Each member of the kidney transplant subcommittee separately rated the quality indicators in advance of a teleconference. The subcommittee members then discussed the individual ratings at the teleconference and agreed upon a group rating for each of the American College of Physicians/Agency for Healthcare Research and Quality domains. Next, we circulated the initial group ratings to each subcommittee member for further feedback and to confirm consensus. Last, we shared the final group ratings with the entire 16-member committee, with further discussion of any ratings that differed by ≥3 points. Formal research ethics board review was not required by Queen’s University based on the Tri-Council Policy Statement for ethical human research, as the focus of the study involved quality indicators and not human participants.

Results

Of the 7 provinces that reported currently using kidney transplant quality indicators, our environmental scan identified a total of 46 unique measures (Table 1). Of the 46 indicators, 9 measured transplant referral and evaluation, 9 waitlist activity and outcomes, 6 hospitalization for transplant surgery, 12 posttransplant care, 6 organ utilization, and 4 the care of living donors. IOM domains of quality that were covered included safe (n = 9, 20%), effective (n = 13, 28%), efficient (n = 11, 24%), timely (n = 6, 13%), person-centered (n = 2, 4%), and equitable (n = 5, 11%) care. Donabedian categories covered included process (n = 19, 41%), outcome (n = 14, 30%), and balancing (n = 13, 28%). We did not identify any structure measures.

Table 2 demonstrates the ratings for all 46 kidney transplant indicators. Overall, we rated 24 (52%) of 46 indicators as “necessary” to distinguish high-quality from low-quality care, 22 (48%) of 46 as “supplemental,” and none as “unnecessary.” The 24 “necessary” indicators comprised 10 process, 9 outcome, and 5 balancing measures that focused on safe (n = 2/24, 8%), effective (n = 10/24, 42%), efficient (n = 6/24, 25%), timely (n = 4/24, 17%), and equitable (n = 2/24, 8%) care. None of the necessary indicators measured person-centered care.

The range of indicators collected by provinces was between 12 and 34. Thirteen indicators were only being measured by a single province and not measured elsewhere. We observed overlap with 14 indicators used by at least 5 of 7 provinces. Of these 14 common indicators, there were 4 process measures, 7 outcome measures, and 3 balancing measures. These common indicators fell into the IOM categories of safe (n = 2), effective (n = 5), efficient (n = 2), timely (n = 1), person-centered (n = 2), and equitable (n = 2) care. The panel rated 10 of these indicators as “necessary” to distinguish high-quality from poor-quality care.

Of the 3 provinces that described local quality improvement initiatives, 2 had initiatives related to increasing access to transplant and living donation (eg, educational and cultural outreach programs). Other initiatives focused on providing safe care including vaccination before transplant, PJP prophylaxis, and cytomegalovirus (CMV)/BK viremia surveillance after transplant. Only 1 initiative was person-centered and focused on improving the posttransplant experience.

Three common themes emerged during the rating process. First, indicators could be precisely defined and specified, but the definitions were variable and dependent on local practice. For example, for the indicator “time from transplant referral to waitlisting,” some programs received most/all required information at the time of referral, whereas other programs must initiate further work-up before wait-listing. Second, the feasibility to collect data or the documentation burden for any given indicator depends largely on data infrastructure or the capabilities of a transplant program’s electronic medical record (EMR). This theme was particularly problematic for indicators that relied on education or quality of life (eg, being informed about transplant as an option). Finally, we rated most indicators (26/46, 57%) as usable for quality improvement (ie, under the influence of health care providers and/or the health care system, with data collection and improvement activities both feasible and acceptable). Exceptions included indicators that change too slowly for rapid cycle improvement activities (eg, kidney transplant prevalence), may not be under the sole control of health care providers (eg, % of highly sensitized individuals who receive a transplant), or may not be modifiable (eg, wait times by blood type).

Discussion

This environmental scan found 46 kidney transplant quality indicators currently being used across transplant programs and kidney agencies in Canada. The indicators spanned all major periods of transplant care, but there were few living donor-specific indicators. Using the IOM framework of health care quality, the majority of indicators were mapped to safe, effective, efficient, and timely care, revealing gaps in measuring person-centered and equitable care. There was variation in the indicators being used across provinces, with only 14 indicators common among most provinces. These results also provide kidney transplant programs with a selection of 24 “necessary” indicators to distinguish high-quality from low-quality care and highlights the need to ensure all domains of health care quality and aspects of kidney transplant care are being monitored. Our study complements ongoing work that aims to achieve consensus on which indicators should be used in kidney transplantation across Canada.
Table 1. Environmental Scan of Current Canadian Kidney Transplant Quality Indicators.

| Institute of Medicine domains of quality | Process                                                                 | Outcome                                                                 | Balancing                                                                 |
|-----------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Safe                                    | % of tacrolimus trough levels in target range (2)                      | Estimated glomerular filtration rate at 1-year posttransplant (7)        | % of recipients with a surgical complication (1)                          |
|                                         | % of recipients on *pneumocystis jiroveci* pneumonia prophylaxis (2)    | % recipients alive after kidney transplantation at 1, 3, and 5 years (6) | % of recipients with a confirmed donor-derived infection (excluding cytomegalovirus and Epstein-Barr virus) (1) |
|                                         |                                                                      | % of recipients who die with a functioning graft each year (4)          | % of recipients hospitalized within 30 days and 1 year of transplant surgery (2) |
|                                         |                                                                      | % of recipients with a surgical complication (1)                        | % of recipients recipients with posttransplant malignancy (2)             |
|                                         |                                                                      | % of recipients with a confirmed donor-derived infection (excluding cytomegalovirus and Epstein-Barr virus) (1) | % of recipients with primary nonfunction (4)                              |
|                                         |                                                                      | % of recipients who die with a functioning graft each year (4)          | % of recipients who develop delayed graft function (5)                   |
|                                         |                                                                      | % of recipients with a surgical complication (1)                        | % of recipients who develop de novo donor-specific antibody (3)          |
|                                         |                                                                      | % of recipients with a surgical complication (1)                        | % of recipients with acute rejection in the first year after transplant (categorized by type and pathology) (6) |
|                                         |                                                                      | % of recipients with a surgical complication (1)                        | % of recipients with new-onset diabetes after transplant in the first year after transplant (1) |
|                                         |                                                                      | % of recipients with a surgical complication (1)                        | % recipients who experienced graft loss each year (4)                    |
| Effective                                | Cold ischemic time (2)                                                 | No. of kidneys donated per year per million (subdivided by living, neurologic determination of death, and donation after circulatory death) (7) | % of individuals who died or who were removed from the waitlist per year (7) |
|                                         | Deceased donor conversion rate (% actual donors/potential donors) (1) | No. of transplants per year per million (subdivided by living, preemptive, deceased, highly sensitized, paired exchange) (7) | Deceased donor quality calculated by kidney donor profile index (3)       |
|                                         |                                                                      | Kidney transplant prevalence (7)                                        | % of potential deceased donors referred for organ donation each year (1) |
|                                         |                                                                      | % of living donor transplants that are preemptive (1)                   |                                                                           |
|                                         |                                                                      | Number of kidney transplants per quarter per program (living donor, deceased donor) (3) |                                                                           |
|                                          |                                                                      |                                                                           |                                                                           |
| Efficient                                | % of eligible individuals with chronic kidney disease referred for kidney transplant evaluation (with and without a living donor) (1) | % of living donor candidates who donate (7) | % of individuals who died or who were removed from the waitlist per year (7) |
|                                          | % of eligible individuals on maintenance dialysis referred for kidney transplant evaluation (with and without a living donor) (1) | % of individuals referred for transplant who receive a transplant (1) | Deceased donor quality calculated by kidney donor profile index (3)       |
|                                          | % of eligible recipients referred for transplant who are waitlisted (3) | Length of stay during transplant surgery (1) | % of potential deceased donors referred for organ donation each year (1) |
|                                          | % of individuals referred for transplant who are waitlisted (3)         |                                                                           |                                                                           |
|                                          | % of individuals referred for transplant who are waitlisted (3)         |                                                                           |                                                                           |
|                                          | % of organs that are exported, imported, and declined (subdivided by region and % accepted, % canceled, % used) (4) |                                                                           |                                                                           |
|                                          |                                                                      |                                                                           |                                                                           |
| Timely                                  | Time from transplant referral to waitlisting (4)                       | % of transplants occurring within the first year of dialysis (3)        | % of individuals who died or who were removed from the waitlist per year (7) |
|                                          | Time from transplant referral to receipt of a living donor transplant (2) |                                                                           |                                                                           |
|                                          | Wait time for deceased donor kidney transplant (subdivided by blood type) (5) |                                                                           |                                                                           |
|                                          | Wait time for living donor evaluation: from donor contact to approval for donation (2) |                                                                           |                                                                           |
|                                          | Wait time for living donor evaluation: from donor contact to donation (2) |                                                                           |                                                                           |
| Person-centered                         | % of eligible highly sensitized individuals enrolled in highly sensitized program (7) | % of highly sensitized individuals who receive a transplant (7) | % of waitlisted KP individuals who receive a KP transplant (1) |
| Equitable                                | % of eligible individuals informed about kidney transplant as an option (subdivided by modality) (1) | % of highly sensitized individuals who receive a transplant (7) |                                                                           |
|                                        | Waitlist characteristics (total no., blood type, age, sex, allocation points) (7) | % of waitlisted KP individuals who receive a KP transplant (1) |                                                                           |
|                                        | No. of pairs entered into kidney paired exchange program per million (5) |                                                                           |                                                                           |
|                                        | No. of living donor candidates per year (1) |                                                                           |                                                                           |

Note. The number in parentheses indicates the number of provinces currently using the listed indicator. KP = kidney-pancreas. 
*Indicators that were common among ≥5 of 7 provinces.
Table 2. Quality Indicators Rated by the American College of Physicians/Agency for Healthcare Research and Quality Performance Measure Criteria Using a Modified Delphi Technique.

| Indicator | Targets important improvements | Performance gap exists | Precisely defined and specified | Feasible to collect | Usable for QI | Final rating | Comments |
|-----------|--------------------------------|------------------------|---------------------------------|---------------------|---------------|--------------|----------|
| Referral and evaluation | | | | | | | |
| % of eligible individuals informed about transplant as an option (subdivided by modality) | 8 | 7 | 8 | 4 | 4 | 7 | 7 Collection of data that accurately capture being informed may be challenging |
| % of eligible individuals with chronic kidney disease referred for kidney transplant evaluation (with and without a living donor) | 8 | 7 | 8 | 6 | 6 | 8 | 8 Collection of data may be challenging and how a living donor contact is defined varies (ie, phone vs Web portal) |
| % of eligible individuals on maintenance dialysis referred for kidney transplant evaluation (with and without a living donor) | 7 | 7 | 8 | 8 | 6 | 8 | 8 |
| % of individuals referred for transplant who are waitlisted | 7 | 5 | 7 | 7 | 7 | 5 | 7 |
| Time from transplant referral to waitlisting | 8 | 4 | 7 | 7 | 7 | 8 | 8 Process for waitlisting may vary between centers |
| % of eligible individuals with chronic kidney disease referred for kidney transplant evaluation (with and without a living donor) | 8 | 7 | 8 | 6 | 6 | 8 | 8 Collection of data may be challenging and how a living donor contact is defined varies (ie, phone vs Web portal) |
| % of living donor transplants that are preemptive | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| No. of pairs entered into kidney paired exchange program per million | 7 | 7 | 8 | 8 | 8 | 7 | 7 |
| Waitlist activity and outcomes | | | | | | | |
| % of eligible individuals referred for transplant who receive a transplant | 7 | 7 | 8 | 7 | 7 | 7 | 7 |
| % of living donor transplants that are preemptive | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| No. of pairs entered into kidney paired exchange program per million | 7 | 7 | 8 | 8 | 8 | 7 | 7 |
| % of eligible highly sensitized individuals enrolled in highly sensitized program | 6 | 5 | 7 | 8 | 8 | 4 | 6 |
| % of highly sensitized individuals who receive a transplant | 6 | 6 | 7 | 7 | 7 | 4 | 5 |
| % of waitlisted KP individuals who receive a KP transplant | 7 | 7 | 8 | 8 | 6 | 6 | 6 |
| % of transplants occurring within the first year of dialysis | 8 | 6 | 8 | 8 | 8 | 6 | 6 |
| % of individuals on waitlist who are inactive or on hold | 7 | 6 | 7 | 7 | 8 | 6 | 6 |
| Waitlist characteristics (total no., blood type, age, sex, allocation points) | 5 | 5 | 6 | 8 | 8 | 4 | 5 |
| % of individuals who died or were removed from the waitlist per year | 8 | 5 | 6 | 8 | 8 | 8 | 8 |
| Number of kidney transplants per quarter per program (living donor, deceased donor) | 8 | 7 | 8 | 8 | 8 | 9 | 8 |
| Hospitalization for transplant surgery | | | | | | | |
| % of recipients with primary nonfunction | 8 | 6 | 4 | 7 | 7 | 7 | 7 Rate is low, but it may provide programs with improvement ideas if causes captured |
| Cold ischemic time | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| % of recipients with a surgical complication | 7 | 6 | 5 | 5 | 3 | 7 | 6 Important to stratify by type; potentially challenging to collect |
| % of recipients with a confirmed donor-derived infection (excluding cytomegalovirus and Epstein-Barr virus) | 5 | 4 | 5 | 5 | 3 | 5 | 4 May provide insight into donor acceptance practices, but challenging to collect and track |
| Length of stay during transplant surgery | 6 | 6 | 8 | 8 | 7 | 7 | 6 |
| % of recipients who develop delayed graft function | 7 | 8 | 7 | 8 | 8 | 7 | 7 Will need risk adjustment for type of kidneys accepted |
| Posttransplant | | | | | | | |
| % of recipients hospitalized within 30 days and 1 year of transplant surgery | 6 | 5 | 7 | 7 | 4 | 5 | 4 Challenging to collect hospitalizations and reasons for hospitalization without an electronic medical record |
| % of recipients on pneumocystis jiroveci pneumonia prophylaxis | 6 | 5 | 8 | 7 | 4 | 7 | 6 Challenging to collect without an electronic medical record |

(continued)
| Indicator | Targets important improvements | Strong level of evidence | Performance gap exists | Precisely defined and specified | Feasible to collect | Usable for QI | Final rating | Comments |
|-----------|-------------------------------|--------------------------|------------------------|-------------------------------|--------------------|---------------|--------------|----------|
| % of tacrolimus trough levels in target range | 7 | 6 | 7 | 4 | 5 | 7 | 6 | Useful for interventions to improve adherence; challenges with multiple measurements, different assays, and electronic medical records |
| % of recipients who develop de novo donor-specific antibody | 7 | 6 | 5 | 5 | 4 | 6 | 5 | Would require standardized screening protocols (ie, routine vs triggered) to precisely define; costly to implement |
| % of recipients with acute rejection in the first year after transplant | 8 | 7 | 7 | 6 | 6 | 7 | 7 | May provide insight on immunosuppression/monitoring practices; pathology may be difficult to collect |
| % of recipients with new-onset diabetes after transplant in the first year after transplant | 7 | 5 | 5 | 5 | 5 | 5 | 5 | Unclear if this is modifiable |
| % of recipients who develop posttransplant malignancy | 7 | 5 | 5 | 3 | 5 | 5 | 5 | Unclear if modifiable, particularly given the prolonged time frame when cancer can develop; granular information on cancer type also needed |
| Estimated glomerular filtration rate at 1 year after transplant | 8 | 8 | 7 | 8 | 8 | 6 | 7 | |
| % of recipients who experienced graft loss each year | 8 | 8 | 7 | 8 | 8 | 8 | 8 | |
| % of recipients alive after kidney transplantation at 1, 3, and 5 years | 8 | 8 | 7 | 8 | 8 | 8 | 8 | |
| Kidney transplant prevalence | 8 | 7 | 7 | 7 | 8 | 4 | 8 | Prevalence does not change rapidly, so difficult to use for improvement |
| % of recipients who die with a functioning graft each year | 6 | 5 | 5 | 5 | 5 | 5 | 6 | May be used for quality assurance. Cause of death would be important to ascertain |

**Organ utilization**

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| No. of kidneys donated per year per million (subdivided by living, neurologic determination of death and donation after circulatory death) | 8 | 8 | 8 | 8 | 8 | 7 | 7 | |
| % of organs that are exported, imported, and declined (subdivided by region and % accepted, % canceled, % used) | 7 | 5 | 7 | 7 | 7 | 6 | 6 | |
| No. of transplants per year per million (subdivided by living, preemptive, deceased, highly sensitized, paired exchange) | 8 | 8 | 8 | 8 | 8 | 7 | 8 | Metric is largely affected by available donor pool |
| Deceased donor quality calculated by kidney donor profile index | 4 | 7 | 7 | 6 | 4 | 4 | 6 | |
| % of potential deceased donors referred for organ donation each year | 6 | 6 | 7 | 7 | 6 | 6 | 5 | |
| Deceased donor conversion rate (% actual donors/potential donors) | 6 | 5 | 7 | 7 | 7 | 5 | 6 | |

**Living donor**

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| No. of living donor candidates per year | 9 | 8 | 8 | 4 | 3 | 7 | 6 | Requires a standard definition of “candidate” |
| % of living donor candidates who donate | 8 | 8 | 8 | 8 | 8 | 7 | 8 | |
| Wait time for living donor evaluation: from donor contact to approval for donation | 8 | 7 | 8 | 8 | 8 | 8 | 8 | |
| Wait time for living donor evaluation: from donor contact to donation | 8 | 5 | 7 | 7 | 6 | 8 | 8 | |

**Note.** Each domain was rated on a 9-point scale, where 1-3 indicated “does not meet criteria,” 4-6 “meets some criteria,” and 7-9 “meets criteria.” After considering and rating each of these domains, the panelists then rated the overall measure (1-3 = unnecessary, 4-6 = supplemental, 7-9 = necessary). QI = quality improvement; KP = kidney-pancreas.
Quality indicators in the field of organ transplantation were evaluated in a systematic review by Brett et al and were collected via a Medline, Embase, and Cochrane Central Register of Controlled Trials search from inception until 2017. A total of 114 unique indicators were found, 65 of which were related to kidney transplant. There are similarities of note between this systematic review and our study. First, both studies categorized indicators by the IOM and Donabedian frameworks and demonstrate the breadth and quantity of measurement occurring in this field. Second, the majority of indicators were in the quality domains of safety and effectiveness, whereas a minority measured equity or person-centeredness. Third, few living donor metrics are being tracked (Brett et al found no living donor metrics in their search of published articles, and our environmental scan found only 4). Important differences are also worth mentioning. The Brett et al systematic review reported metrics published in the worldwide transplant literature, whereas our study evaluates the current state of quality indicator use in Canada. Brett et al classified 23% of their metrics as structure measures, including transplant center volume, appointment no-show rates, and program costs, whereas our study identified no structure metrics. Although the reasons for this remain unclear, it may be that programs may not fully understand the definitions of various categories of quality metrics, which may limit their reporting. Finally, our study used the American College of Physician/Agency for Healthcare Research and Quality criteria to rate the indicators and evaluate their strengths and weaknesses.

Our study also identified several important issues with kidney transplant quality measurement currently occurring in Canada that warrant further attention. Notably, not all areas of transplantation are receiving equal attention, most notably gaps in living kidney donation, which is particularly important because rates of living donation have been stagnant in Canada for some time. Similarly, although health care systems around the world are being redesigned to achieve the quadruple aim (improve population health, experience of care, reduce per capita costs and increase joy in work), our study found no patient-reported outcome or experience measures (eg, functional impairment or quality of life) or cost/resource utilization indicators being routinely measured. We also identified many “necessary” process (n = 10) measures, with 70% used by more than 1 province. This is important to point out as process measures are more easily measured and can demonstrate change more rapidly than outcome measures, making them an important component of rapid-cycle microsystem quality improvement activities.

Recently, 2 Canadian studies attempted to address some of the described shortcomings. The first was a Canadian consensus workshop of key stakeholders in transplantation (physicians, patient representatives, allied health) that reviewed potential quality indicators according to predefined criteria (eg, relevant, actionable, measurable) and provided a recommendation of essential, optional, or exclude. The second study was a Delphi panel to achieve consensus on quality indicators used to measure the efficiency of the living kidney donor evaluation. An important observation from the indicators selected in these 2 studies is that the equity domain of quality continues to lack representation, as confirmed in our environmental scan. In the first workshop described above, indicators classified as equitable care included donor candidates deemed suitable to donate and number of living donor kidney transplants performed. In the living donor Delphi panel, there were no measures of equity. Equitable care metrics are important to develop because of known existing health care disparities in minority populations. For example, women, individuals of lower socioeconomic status, and those of African or Indigenous backgrounds have consistently been shown to have a reduced likelihood of transplant referral, wait-listing, and subsequent kidney transplant, emphasizing the need to include patients and vulnerable populations as key stakeholders in an effort to fill the identified gaps. Another important observation was the sheer number of indicators that resulted from these 2 studies (54 and 26, respectively), in addition to the 46 indicators we found. Therefore, prioritization of indicators will need to occur as transplant programs may not have the means to undertake this amount of measurement and corresponding quality improvement activities. Our goal of this study is to complement the ongoing efforts by Knoll et al and Garg et al in prioritizing indicators. Ideally, future indicators could be developed and piloted at a local level prior to them being implemented at a national level. A key consideration would be to promote regular reevaluation of whether these indicators remain valid and suitable for ongoing use and retire those indicators that no longer represent the interests of the various stakeholders. Ideally this reevaluation could be done at a national level to maintain alignment between independent programs. Our 16-member pan-Canadian quality collaborative is currently working with senior leadership across the country (Canadian Senior Renal Leaders Community of Practice group) to prioritize quality indicators in the various domains of kidney care. We hope this will help focus future local quality improvement initiatives on a few key areas and encourage collaboration between centers embarking on similar initiatives.

Our study assists the transplant community with these prioritization activities by identifying 24 “necessary” indicators (10 measured by 5 of 7 provinces) that programs are already devoting resources to as a starting point for standardization across Canada. Strengths of this work include the structured approach to indicator categorization and evaluation through applying the IOM and Donabedian frameworks along with the criteria used by American College of Physicians/Agency for Healthcare Research and Quality. In addition, we involved nephrologists with advanced training and real-life expertise in kidney transplantation and/or quality improvement to ensure relevance to frontline improvement efforts. Our panel included individuals who represent most regions of Canada.
which helped ensure that quality indicators would be relevant across different health care settings.

Limitations deserve mention. First, we did not receive indicators from all kidney transplant centers across Canada, and therefore our list of indicators is not exhaustive. Second, our study focused on identifying and rating current indicators without clarifying the operational definitions or how each indicator is being used for quality improvement. Third, we did not automatically include indicators from the Canadian Organ Replacement Register (a nationwide database reporting long-term trends in organ donation and transplantation) unless explicitly stated by programs that they were used for quality improvement activities. Fourth, our evaluation of indicators was not anonymized, which can result in the group arriving at conclusions primarily because others are doing so (the bandwagon effect). Fifth, the panel was composed mainly of physicians and thus did not include the valuable perspectives of other stakeholders, including administrators, allied health professionals, and, importantly, patients. Finally, there is subjectivity when using the IOM classification to categorize indicators. For example, the time from transplant referral to receipt of a transplant could be classified as efficient or timely care. The determination of IOM domain should ideally be based on how that indicator is used to drive quality improvement activities.

In summary, we identified 46 kidney transplant quality indicators currently being measured across Canada. There was a paucity of living donor indicators, and we found that the majority of indicators focused on safe, effective, and efficient care, with significant gaps in measuring person-centered and equitable care. Ten of the necessary indicators were common among most provinces. We hope this overview serves as a useful guide and starting point that supports ongoing efforts to develop, standardize, and curate kidney transplant indicators across Canada.

Acknowledgments
The authors value the support and guidance from Adeera Levin throughout the design and execution of this work. The other 12 volunteer quality committee members include the following: William Beaubien-Souligny, Daniel Blum, Lisa Dubrofsky, Claire Harris, Jay Hingwala, Ali Ibrahim, Amber Molnar, Priya Mysore, Kris Poinen, Sachin Shah, Karthik Tennankore, and Alison Thomas.

Consent for Publication
All authors approved the final version of this manuscript.

Availability of Data and Materials
The data and material are available from corresponding author upon reasonable request.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: T.G. has participated in consultancy for Paladin Labs Inc. A.V. has participated in advisory boards/consultancy work for Paladin Labs Inc. S.A.S. has received speaking fees from Sanofi and Baxter Canada. S.Y. has no conflicts of interest relevant to this study. All authors approved the final version of the submitted manuscript. We certify that this manuscript nor one with substantially similar content has been published or is being considered for publication elsewhere.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: S.A.S. is supported by a Kidney Research Scientist Core Education and National Training (KRES Cent) Program New Investigator Award (co-funded by the Kidney Foundation of Canada, Canadian Society of Nephrology, and Canadian Institutes of Health Research).

ORCID iDs
Tamara Glavinovic https://orcid.org/0000-0001-6462-8858
Amanda J. Vinson https://orcid.org/0000-0002-9345-5252
Samuel A. Silver https://orcid.org/0000-0002-1843-6131

Supplemental Material
Supplemental material for this article is available online.

References
1. Sharma S, Sarnak MJ. Epidemiology: the global burden of reduced GFR: ESRD, CVD and mortality. Nat Rev Nephrol. 2017;13(8):447-448. doi:10.1038/nrneph.2017.84.
2. Kostro IZ, Hellmann A, Kobiela J, et al. Quality of life after kidney transplantation: a prospective study. Transplant Proc. 2016;48:50-54. doi:10.1016/j.transproceed.2015.10.058.
3. Canadian organ replacement register annual report: treatment for end-stage organ failure in Canada, 2003 to 2012. Ottawa, ON: Canadian Institute for Health Information. Published 2014. https://secure.cihi.ca/free_products/2014 CORR_Report_EN.pdf. Accessed June 15, 2021.
4. Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150:252-259. doi:10.1001/jamasurg.2014.2038.
5. Naylor KL, Dixon SN, Garg AX, et al. Variation in access to kidney transplantation across renal programs in Ontario, Canada. Am J Transplant. 2017;17:1585-1593. doi:10.1111/ajt.14133.
6. Kim SJ, Gill JS, Knoll G, et al. Referral for kidney transplantation in Canadian provinces. J Am Soc Nephrol. 2019;30:1708-1721. doi:10.1681/ASN.2019020127.
7. Habbous S, Arnold J, Begen MA, et al. Duration of living kidney transplant donor evaluations: findings from 2 multicenter cohort studies. Am J Kidney Dis. 2018;72:483-498. doi:10.1053/j.ajkd.2018.01.036.
8. Habbous S, Woo J, Lam NN, et al. The efficiency of evaluating candidates for living kidney donation: a scoping review. Transplant Direct. 2018;4:e394. doi:10.1097/TXD.0000000000000833.
9. Brett KE, Ertel E, Grimshaw J, Knoll GA. Perspectives on quality of care in kidney transplantation: a semistructured
interview. Transplant Direct. 2018;4:e383. doi:10.1097/TPD.0000000000000820.
10. Brett KE, Ritchie LJ, Ertel E, Bennett A, Knoll GA. Quality metrics in solid organ transplantation: a systematic review. Transplantation. 2018;102(7):e308-e330. doi:10.1097/TP.0000000000002149.
11. Institute of Medicine, Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001.
12. Donabedian A. The quality of care: how can it be assessed? JAMA. 1988;260:1743-1748. doi:10.1001/jama.260.12.1743.
13. Stelfox HT, Straus SE. Measuring quality of care: considering measurement frameworks and needs assessment to guide quality indicator development. J Clin Epidemiol. 2013;66:1320-1327. doi:10.1016/j.jclinepi.2013.05.018.
14. Agency for Healthcare Research and Quality. AHRQ quality indicators. Published 2012. http://www.qualityindicators.ahrq.gov/. Accessed June 15, 2021.
15. Greenberg A, Angus H, Sullivan T, Brown AD. Development of a set of strategy-based system-level cancer care performance indicators in Ontario, Canada. Int J Qual Health Care. 2005;17:107-114. doi:10.1093/intqhc/mzi007.
16. MacLean CH, Kerr EA, Qaseem A. Time out—charting a path for improving performance measurement. N Engl J Med. 2018;378:1757-1761. doi:10.1056/NEJMp1802595.
17. Mendu ML, Tummalapalli SL, Lentine KL, et al. Measuring quality in kidney care: an evaluation of existing quality metrics and approach to facilitating improvements in care delivery. J Am Soc Nephrol. 2020;31:602-614. doi:10.1681/ASN.2019090869.
18. Chia-Chien Hsu BAS. The Delphi technique: making sense of consensus. Practical Assessment, Research, and Evaluation. 2007;12:10.
19. Guittmann A, Razzaq A, Lindsay P, Zagorski B, Anderson GM. Development of measures of the quality of emergency department care for children using a structured panel process. Pediatrics. 2006;118:114-123. doi:10.1542/peds.2005-3029.
20. Kroger E, Tourigny A, Morin D, et al. Selecting process quality indicators for the integrated care of vulnerable older adults affected by cognitive impairment or dementia. BMC Health Serv Res. 2007;7:195. doi:10.1186/1472-6963.
21. Lindsay P, Schull M, Bronskill S, Anderson G. The development of indicators to measure the quality of clinical care in emergency departments following a modified-Delphi approach. Acad Emerg Med. 2002;9:1131-1139. doi:10.1111/j.1553-2712.2002.tb01567.x.
22. Bell CM, Brener SS, Comrie R, et al. Quality measures for medication continuity in long-term care facilities, using a structured panel process. Drugs Aging. 2012;29:319-327. doi:10.2165/11599150-000000000.
23. Morris AM, Brener S, Dresser L, et al. Use of a structured panel process to define quality metrics for antimicrobial stewardship programs. Infect Control Hosp Epidemiol. 2012;33:500-506. doi:10.1086/665324.
24. Jeffs L, Law MP, Straus S, Cardoso R, Lyons RF, Bell C. Defining quality outcomes for complex-care patients transitioning across the continuum using a structured panel process. BMJ Qual Saf. 2013;22:1014-1024. doi:10.1136/bmjqs-2012.
25. Knoll GA, Fortin MC, Gill J, et al. Measuring quality in living donation and kidney transplantation: moving beyond survival metrics. Kidney Int. 2020;98:860-869. doi:10.1016/j.kint.2020.07.014.
26. Horvat LD, Shariat SZ, Garg AX, Donor Nephrectomy Outcomes Research (DONOR) Network. Global trends in the rates of living kidney donation. Kidney Int. 2009;75:1088-1098. doi:10.1038/ki.2009.20.
27. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood). 2008;27:759-769. doi:10.1377/hlthaff.27.3.759.
28. Whittington JW, Nolan K, Lewis N, Torres T. Pursuing the triple aim: the first 7 years. Milbank Q. 2015;93:263-300. doi:10.1111/1468-0009.12122.
29. Mountford J, Shojania KG. Refocusing quality measurement to best support quality improvement: local ownership of quality measurement by clinicians. BMJ Qual Saf. 2012;21:519-523. doi:10.1136/bmjqs-2012-000859.
30. Garg AX, Habboush S, Barnieh L, et al. A RAND-modified Delphi on key indicators to measure the efficiency of living kidney donor candidate evaluations. Clin J Am Soc Nephrol. 2020 Oct;7(10):1464-1473. doi:10.2215/CJN.03780320. Epub 2020 Sep 24. PMID: 32972951; PMCID: PMC7536767.
31. Young BA, Hall Y, Rodriguez RA. Health disparities in chronic kidney disease: are we making any progress? Nephrol News Issues. 2009;23(48):50-41.
32. Crews DC, Liu Y, Boulware LE. Disparities in the burden, outcomes, and care of chronic kidney disease. Curr Opin Nephrol Hypertens. 2014;23:298-305. doi:10.1097/01.mnh.0000444822.25991.f6.
33. Patzer RE, Amaral S, Wasse H, Volkova N, Kleinbaum D, McClellan WM. Neighborhood poverty and racial disparities in kidney transplant waitlisting. J Am Soc Nephrol. 2009;20:1333-1340. doi:10.1681/ASN.2008030335.
34. Melk A, Babitsch B, Borchert-Morlins B, et al. Equally interchangeable? how sex and gender affect transplantation. Transplantation. 2019;103:1094-1110. doi:10.1097/TP.0000000000002655.
35. Yeates KE, Cass A, Sequist TD, et al. Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation. Kidney Int. 2009;76:659-664. doi:10.1038/ki.2009.236.
36. Erdmann R, Morrin L, Harvey R, Joya L, Clifford A, Soroka S. Canadian senior renal leaders community of practice: vulnerable populations with chronic kidney disease-evidence to inform policy. Can J Kidney Health Dis. 2020;7:2054358120930977. doi:10.1177/2054358120930977.